Group purchasing organizations have an important purpose in healthcare, but there are some concerns, explained Martin Makary, MD, MPH, a surgical oncologist and chief of the Johns Hopkins Islet Transplant Center.
Group purchasing organizations have an important purpose in healthcare, but there are some concerns, explained Martin Makary, MD, MPH, a surgical oncologist and chief of the Johns Hopkins Islet Transplant Center.
Transcript
Why do hospitals use group purchasing organizations for getting medications, medical devices, and devices? What are some of the pros and cons or using these organizations?
I recently summarized what I believe to be the advantage and disadvantages of GPOs [Group Purchasing Organizations] in an article in JAMA, and in my research, I learned a couple of things. Number 1, GPOs serve an important purpose in healthcare. They save hospitals all of the legal and contracting work of going out there and writing contracts with hundreds of different vendors. Just like they would buy supplies from an Office Depot or Home Depot catalogue, similarly, GPOs make many products available.
Where I have significant concerns is in a pay-to-play fee system that GPOs have adopted through a loophole or an exemption that’s been passed into law of the Sherman Anti-Trust Act. That exemption to the Sherman Anti-Trust act allows them legally to demand fees from manufacturers and pharma companies to be listed in the catalogues or to have premium listing or even sometimes sole supplier listing in a catalogue. It’s generally anti-competitive, it’s not good for patients, and when the GPOs are sharing back some of the profits to the hospital who is left holding the bag? Those high costs that the manufacturers build into the price of the medication or device gets passed all the way through to the patient.
So, we have stories of individuals patients paying absurd amounts of money for a medication in a hospital setting that’s been around for a long time. How do you explain a sudden shortage of a certain medication that’s been around for 50 years? Sometimes it’s the sole supplier contracting that allows monopoly dominance in certain markets that allows that supply chain to get flimsy.
There are a lot of complex issues around GPOs. I don’t think GPOs are bad. I think they serve a valuable purpose in healthcare. But, I do personally and philosophically believe that we should get rid of kickbacks in GPO industry, which are called administrative fees, and we should get rid of kickbacks that are in the PBM [pharmacy benefit manager] world that are called rebates, and we should get rid of all kickbacks in healthcare.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More